{
    "Rank": 157,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03501056",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CD3-MUC1 in lung cancer"
                },
                "Organization": {
                    "OrgFullName": "Fuda Cancer Hospital, Guangzhou",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer",
                "OfficialTitle": "Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Lung Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "May 2020",
                "OverallStatus": "Withdrawn",
                "WhyStopped": "No participants enrolled",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 27, 2018",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "May 25, 2020",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "July 27, 2020",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "April 10, 2018",
                "StudyFirstSubmitQCDate": "April 10, 2018",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "April 18, 2018",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "October 13, 2020",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "October 19, 2020",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Fuda Cancer Hospital, Guangzhou",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.",
                            "CollaboratorClass": "INDUSTRY"
                        }
                    ]
                }
            },
            "OversightModule": {
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced lung cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for lung cancer.",
                "DetailedDescription": "Primary pulmonary carcinoma is one of the most common malignancies in China, ranking first in all malignant tumors and mortality.Immunetherapy is considered to be one of the most promising means of human against cancer. This is a phase II clinical trial of single- center, The investigators plan to recruit for 90 patients with advanced lung cancer,and all patients are divided into three groups.one group will receive cryotherapy, one group will receive conventional therapy\uff0cand the rest one will receive mixed liquor of activated CIK and anti-CD3-MUC1 bispecific antibody together with cryotherapy.\n\nThe result of this study was statistic and analysed with the record of Response Evaluation Criteria In Solid Tumors(RECIST1.1) evaluation standard."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Advanced Lung Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "PD-1 activated CIK",
                        "MUC1",
                        "Bispecific antibody",
                        "lung cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignInterventionModelDescription": "This is a phase II clinical trial of single-center, and it will divide into three groups.",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "Quadruple",
                        "DesignMaskingDescription": "With the method of minimum randomized dynamic random by the interactive network response system (IWRS),Participants were assigned to three groups,receive cryotherapy,conventional therapy, and activated CIK armed with anti-CD3-MUC1 bispecific antibody together with cryotherapy .every participant has a unique identification number and emergency letter which have the information of group.",
                        "DesignWhoMaskedList": {
                            "DesignWhoMasked": [
                                "Participant",
                                "Care Provider",
                                "Investigator",
                                "Outcomes Assessor"
                            ]
                        }
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "0",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "cryotherapy",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "the maximum tumor length\u22652 cm\uff0ccool down the lesion,result in degeneration, necrosis or loss of the lesion.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Procedure: Cryotherapy"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Cryotherapy & Activated CIK and bispecific antibody",
                            "ArmGroupType": "Active Comparator",
                            "ArmGroupDescription": "the maximum tumor length\u22652cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Biological: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer",
                                    "Procedure: Cryotherapy"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "conventional therapy",
                            "ArmGroupType": "No Intervention",
                            "ArmGroupDescription": "In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Biological",
                            "InterventionName": "Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer",
                            "InterventionDescription": "CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Cryotherapy & Activated CIK and bispecific antibody"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "Cryotherapy",
                            "InterventionDescription": "the maximum tumor length\u22652 cm\uff0ccool down the lesion,result in degeneration, necrosis or loss of the lesion.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Cryotherapy & Activated CIK and bispecific antibody",
                                    "cryotherapy"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Objective response rate",
                            "PrimaryOutcomeDescription": "ORR.The proportion of patients who had a best response rating of complete response and partial response.",
                            "PrimaryOutcomeTimeFrame": "1 year"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Progression-free survival",
                            "SecondaryOutcomeDescription": "PFS.The time of patients from randomization to death caused by the progression of the tumor or any cause.",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Time tumor progression",
                            "SecondaryOutcomeDescription": "TTP.The time of patient from randomization to objective progress of the tumor.",
                            "SecondaryOutcomeTimeFrame": "1 year"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Disease control rate",
                            "SecondaryOutcomeDescription": "DCR.The proportion of patients who had a best response rating of complete response, partial response,or stable disease.",
                            "SecondaryOutcomeTimeFrame": "1 year"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Overall survival",
                            "SecondaryOutcomeDescription": "OS.The time of patient from randomization to death caused by any cause",
                            "SecondaryOutcomeTimeFrame": "3 years"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Symptom remission rate",
                            "SecondaryOutcomeDescription": "SRR. The proportion of symptoms are alleviated in all evaluative cases.",
                            "SecondaryOutcomeTimeFrame": "1 year"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\n18-75 years old\nThe patient is diagnosed as advanced lung cancer,MUC1 is positive\nThere is at least one tumor should be measured,and length\u226510mm of focus not at lymph node or length\u226510mm of focus at lymph node\nThe patient can't tolerate system(systemic chemotherapy/molecular targeted therapy) or local therapies\nIf the patient received adjuvant chemotherapy after local treatment,the time should be more than 4 weeks after the end of chemotherapy, and disease progression or metastasis patients can also assigned into the group\nThe time of surgical treatment\u2265 3 months ;At the end of the intervention,radiotherapy and the end of the ablation time is more than 4 weeks\nThe expected survival time \u226512 weeks\nThe patient did not took any antitumor drugs within 4 weeks(any antitumor drugs, Chinese patent medicine including Delisheng injection,Kanglaite injection, Aidi injection\nNo serious disease are conflicts with the solution(such as autoimmune disease,immunodeficiency,organ transplantation)\nSign the informed consent\n\nExclusion Criteria:\n\nmedium or above ascites\nPatient of second primary tumor or multiple primary cancer\nPatients of T cell lymphoma\u3001myeloma,and patients are using immunosuppressant\nSystemic autoimmune diseases, allergic constitution or immunocompromised patients\nPatients of chronic diseases need immune stimulant or hormone therapy\nPatients of active bleeding or coagulant function abnormality\uff08PT>16s\u3001APTT>43s\u3001TT>21s\u3001INR\u22652\uff09,and patients of bleeding tendency or are receiving thrombolysis and anticoagulation and antiplatelet therapy\nWomen who is pregnant or during breast feeding or plan to pregnant in 2 years,and not willing to contraception during the test\nPatients with brain\u3001dura mater metastases or history of psychogenic\nGastrointestinal bleeding in the past six months or have clear gastrointestinal bleeding tendency,such as: patients of local active ulcerative lesions, defecate occult blood + + above shall not enter into group; defecate occult blood + depend on gastroscopy\nPatients with severe stomach/esophageal varices and need for intervention treatment\nPatients with abdominal fistula, gastrointestinal perforation or abdominal abscess within 4 weeks before the first treatment\nPositive for HIV antibody\nPatients who are allergic to computed tomography (CT) and magnetic resonance imaging (MRI) contrast agents at the same time, can't imaging assay\nPatients accepted any experimental drugs or pilot medical apparatus and instruments in the past 4 weeks of first treatment\nOther reasons the researchers think not suitable",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "75 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Jibing Chen, Doctor",
                            "OverallOfficialAffiliation": "Guangzhou Fuda Cancer Hospital",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Institutional Review Board of Guangzhou Fuda Cancer Hospital",
                            "LocationCity": "Guangzhou",
                            "LocationState": "Guangdong",
                            "LocationZip": "510665",
                            "LocationCountry": "China"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000000906",
                            "InterventionMeshTerm": "Antibodies"
                        },
                        {
                            "InterventionMeshId": "D000018033",
                            "InterventionMeshTerm": "Antibodies, Bispecific"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000007155",
                            "InterventionAncestorTerm": "Immunologic Factors"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M17050",
                            "InterventionBrowseLeafName": "Vaccines",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9874",
                            "InterventionBrowseLeafName": "Immunoglobulins",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3915",
                            "InterventionBrowseLeafName": "Antibodies",
                            "InterventionBrowseLeafAsFound": "Given",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M19884",
                            "InterventionBrowseLeafName": "Antibodies, Bispecific",
                            "InterventionBrowseLeafAsFound": "Ambulatory Blood Pressure",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M18891",
                            "InterventionBrowseLeafName": "Muromonab-CD3",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9891",
                            "InterventionBrowseLeafName": "Immunologic Factors",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}